We now know that activation of MET or HER2 amplification, acquisition of mutations in BRAF, PIK3CA, and KRAS, histological transformation to small cell lung cancer (SCLC), and epithelial-to-mesenchymal transition (EMT) are major reasons (30–35). The gene discussed is KRAS; the disease is small cell lung carcinoma.